September 2026 could be an important month for the biopharmaceutical industry, with 5 potentially significant therapies and technologies approaching FDA decisions. These developments highlight where innovation is heading and where demand for specialist life sciences talent could follow.
1. Scholar Rock: Apitegromab for Spinal Muscular Atrophy (SMA)
A promising new treatment for spinal muscular atrophy (SMA), a serious genetic disease that causes progressive muscle weakness. Unlike gene-targeted therapies, it works by inhibiting myostatin to support muscle growth and function.
Hiring outlook: Increased demand for rare-disease commercial, medical affairs, market access and patient-support professionals, particularly those with experience working across specialist treatment centres and complex reimbursement pathways.
2. Nuvalent: Zidesamtinib for ROS1-Positive Lung Cancer
A next-generation targeted therapy being developed for patients with ROS1-positive NSCLC. Targeted therapies can offer significant benefits, but resistance to existing ROS1 inhibitors remains a challenge, creating a need for effective next-generation treatments.
Hiring outlook: Will drive need for specialist oncology MSLs, commercial professionals, market-access specialists and regulatory talent, particularly candidates with experience in precision oncology and targeted therapies.
3. Ionis Pharmaceuticals: Zilganersen for Alexander Disease
An antisense therapy for the rare and devastating neurodegenerative disorder, highlighting the growing potential of RNA-targeted medicines in diseases with limited treatment options.
Hiring outlook: Rare neurological launches require highly specialised expertise, leading to increased demand for medical affairs, regulatory and patient-engagement professionals with experience in rare disease and RNA-based technologies.
4. Ultragenyx: UX111 for Sanfilippo Syndrome Type A
A gene therapy for the rare inherited metabolic disorder affecting primarily children, targeting the underlying genetic cause rather than simply managing symptoms. For a condition with progressive neurological deterioration, the potential to intervene earlier is particularly significant.
Hiring outlook: Gene-therapy launches require highly specialised teams spanning CMC, manufacturing, quality, regulatory and medical affairs. Experienced advanced-therapy talent is already a relatively scarce resource, making recruitment a critical consideration for successful commercialisation.
5. Telix Pharmaceuticals: Pixclara for Glioma Imaging
A diagnostic imaging agent using fluorine-18 FET PET to help clinicians distinguish recurrent or progressive glioma from treatment-related changes, supporting more informed treatment decisions and patient monitoring.
Hiring outlook: This product highlights the growing convergence of pharmaceuticals, diagnostics and nuclear medicine. Increasing need for professionals with experience spanning regulatory affairs, medical affairs and specialist commercialisation.
What do these potential approvals mean for recruitment?
As medicines become more specialised, so does the talent required to bring them to market. The biggest recruitment opportunities are likely to centre around:
- Rare-disease commercialisation
- Medical affairs and MSL teams
- Precision oncology
- Gene therapy and advanced therapies
- RNA and antisense technologies
- Market access and reimbursement
- Regulatory affairs
- Specialist diagnostics and imaging
Specialist experience is becoming increasingly valuable and expertise in these areas can open doors across a growing number of emerging biotech and pharmaceutical companies.
The next generation of medicines will require the next generation of specialist talent, and recruitment is becoming an increasingly important part of the launch strategy.
You might also like to read:
